PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 2026Rheumatology and Therapy0 citationsOpen Access

Upadacitinib Treatment Persistence and Outcomes in Canadian Patients with Inflammatory Arthritis

Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study

View Full Paper

Authors

JPJanet E. PopeJPJayeshkumar PatelCSChristopher D. Saffore

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates medication persistence and clinical outcomes in Canadian patients, suggesting effective support systems.

Key Points

  • This study aims to evaluate medication persistence and clinical outcomes among Canadian patients with inflammatory arthritis receiving upadacitinib.
  • Data collected from patients enrolled in the AbbVie Care patient support program from January 2020 to July 2025.
  • Evaluated first prescription fill rates, medication persistence, and Health Assessment Questionnaire Disability Index scores.
  • Analyzed demographic characteristics and patient satisfaction within the program.
  • Medication persistence in RA was 73% at 12 months and 51% at 48 months.
  • Patients with RA had a mean reduction in HAQ-DI of -0.40 with 62% achieving minimal clinically important difference.
  • 90% of surveyed RA patients reported high satisfaction with the patient support program.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pope et al. (2026) studied this question.

synapsesocial.com/papers/6a13e8680e02ee3982d332f2https://doi.org/10.1007/s40744-026-00859-w
Ask AI
Helpful
Bookmark
Share
View Full Paper